The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis

References

• Biogen Idec IncPrescription information: Amevive (Alefacept)2005Cambridge, MA, U S A
   Google Scholar
• ChristophersEPsoriasis – epidemiology and clinical spectrumClin Exp Dermatol2001263142011422182
   PubMed Web of Science ®Google Scholar
• ElderJTNairRPHenselerTThe genetics of psoriasis 2001: the odyssey continuesArch Dermatol200113714475411708947
   PubMed Web of Science ®Google Scholar
• EllisCNKruegerGGTreatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytesN Engl J Med20013452485511474662
   PubMed Web of Science ®Google Scholar
• EllisCNMordinMMAdlerEYEffects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trialAm J Clin Dermatol20034131912553852
   PubMed Web of Science ®Google Scholar
• FeldmanSRMenterAKooJYImproved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasisBr J Dermatol20041503172614996104
   PubMed Web of Science ®Google Scholar
• FinlayAYKhanGKDermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical useClin Exp Dermatol19941921068033378
   PubMed Web of Science ®Google Scholar
• FinlayAYSalekMSHaneyJIntramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasisDermatology20032063071512771471
   PubMed Web of Science ®Google Scholar
• GoffeBPappKGrattonDAn integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyClin Ther20052719122116507377
   PubMed Web of Science ®Google Scholar
• GordonKBKruegerGGvan de KerkohfPEfficacy and safety of multiple courses of alefacept in combination with other psoriasis therapiesJ Am Acad Dermatol20055218315627120
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGRemittive effects of intramuscular alefacept in psoriasisJ Drugs Dermatol20032624814711140
   PubMedGoogle Scholar
• GordonKBVaishnawAKO’GormanTreatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T cell countsArch Dermatol200313915637014676071
   PubMed Web of Science ®Google Scholar
• GottliebABBoehnckeWHDarifMSafety and efficacy of alefacept in elderly patients and other special populationsJ Drugs Dermatol200547182416302557
   PubMedGoogle Scholar
• GottliebABCasaleTBFrankelECD4+ T cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyJ Am Acad Dermatol2003498162514576659
   PubMed Web of Science ®Google Scholar
• HodakEDavidMAlefacept: a review of the literature and practical guidelines for managementDermatol Ther2004173839215379773
   PubMedGoogle Scholar
• KormanNJMoulDKAlefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical useSemin Cutan Med Surg20052410815900794
   PubMed Web of Science ®Google Scholar
• KorverJEvan de KerkhofPCPaschMCAlefacept treatment of psoriatic nail disease: how severe should nail psoriasis be?J Am Acad Dermatol200654742316546613
   PubMed Web of Science ®Google Scholar
• KraanMCvan KuijkAWDinantHJAlefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritisArthritis Rheum20024627768412384938
   PubMed Web of Science ®Google Scholar
• KrellJMUse of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanerceptJ Am Acad Dermatol200654109910116713481
   PubMed Web of Science ®Google Scholar
• KruegerGKooJLebwohlMThe impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol2001137280411255325
   PubMed Web of Science ®Google Scholar
• KruegerGGPappKAStoughDBA randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad, Dermatol2002478213312451365
   PubMed Web of Science ®Google Scholar
• KruegerJGThe immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol20024612311756941
   PubMed Web of Science ®Google Scholar
• LangleyRGChermanAMGuptaAKAlefacept: an expert review concerning the treatment of psoriasisExpert Opin Pharmacother2005623273316218892
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet2003361119720412686053
   PubMed Web of Science ®Google Scholar
• LebwohlMChristophersELangleyRAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol20031397192712810502
   PubMed Web of Science ®Google Scholar
• LiuCMMcKennaJKKruegerGGAlefacept: a novel biologic in the treatment of psoriasisDrugs Today2004409617415645008
   PubMed Web of Science ®Google Scholar
• LoweNJGonzalezJBagelJRepeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyInt J Dermatol2003422243012653922
   PubMed Web of Science ®Google Scholar
• LubaKMStulbergDLChronic plaque psoriasisAm Fam Physician2006736364416506705
   PubMed Web of Science ®Google Scholar
• MajeauGRMeierWJimmoBMechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic miceJ Immunol19941522753677511625
   PubMed Web of Science ®Google Scholar
• MenterACatherJCBakerDThe efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasisJ Am Acad Dermatol20065461316384756
   PubMed Web of Science ®Google Scholar
• MillerGTHochmanPSMeierWSpecific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responsesJ Exp Med1993178211227686212
   PubMed Web of Science ®Google Scholar
• MyersWChristiansenLGottliebABTreatment of palmoplantar psoriasis with intramuscular alefaceptJ Am Acad Dermatol200553S127916021161
   PubMed Web of Science ®Google Scholar
• OrtonneJPLebwohlMEm GriffithsGCAlefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasisEur J Dermatol2003131172312695125
   PubMed Web of Science ®Google Scholar
• PappKAThe long-term efficacy and safety of new biological therapies for psoriasisArch Dermatol Res200629871516691429
   PubMed Web of Science ®Google Scholar
• ParrishCASoberaJORobbinsCMAlefacept in the treatment of psoriatic nail disease: a proof of concept studyJ Drugs Dermatol200653394016673801
   PubMedGoogle Scholar
• RobertCKupperTSInflammatory skin diseases, T cells, and immune surveillanceN Engl J Med199934118172810588968
   PubMed Web of Science ®Google Scholar
• SandersMEMakgobaMWSharrowSOHuman memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma productionJ Immunol1988140140172894392
   PubMed Web of Science ®Google Scholar
• ScheinfeldNAlefacept: a safety profileExpert Opin Drug Saf2005a49758516255657
   PubMedGoogle Scholar
• SweetserMTWoodworthJSwanSResults of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefaceptDermatol Online J200612116638415
   PubMedGoogle Scholar
• ThaciDPatzoldSKaufmannRTreatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two casesBr J Dermatol200515210485015888169
   PubMed Web of Science ®Google Scholar
• VaishnawAKTenHoorCNPharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administrationJ Pharmacokinet Pharmacodyn2002294152612795239
   PubMed Web of Science ®Google Scholar
• van de KerkhofPGriffithsCEChristophersEAlefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequateDermatology20052112566316205071
   PubMed Web of Science ®Google Scholar
• WongVKLebwohlMThe use of alefacept in the treatment of psoriasisSkin Therapy Lett2003812714610613
   PubMedGoogle Scholar
• Yeung-YueKAronsonPMurakawaGClinical improvment of palmoplantar pustular psoriasis with alefaceptJ Am Acad Dermatol200552Proceeding of the 63rd Annual Meeting of the American Academy of DermatologyNew Orleans, LA, USA179
   Google Scholar